| Expression pattern: |
UP |
| Associated gene: |
OGA, FBP1, AGO2 |
| Associated microRNA: |
miR-503-5p |
| Biological function: |
exo-circCRIM1 promotes TNBC progression, tumor growth, invasion, metastasis and TNBC cell proliferation; circCRIM1 depletion restrains TNBC cell growth. |
| Molecular mechanism: |
exo-circCRIM1 acts as a ceRNA that absorbs miR-503-5p, activates OGA, and regulates the OGA/FBP1 signaling pathway; OGA negatively regulates FBP1 by decreasing its protein stability and promoting ubiquitination. |
| Biological pathway or process: |
ceRNA regulation (promotes); proliferation (promotes); invasion (promotes); metastasis (promotes); ubiquitination (promotes); mRNA stability (other); immune regulation (other); other pathway/process (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RT-qPCR; circRNA-seq; Clinical Sample Validation; Bioinformatics Analysis; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Transfection; CCK8; Western Blot; Co-IP; IHC (Immunohistochemistry); In Vivo Animal Model; Survival Analysis |
| Clinical significance: |
Elevated exo-circCRIM1 in TNBC patients with high body fat percentage is associated with relatively low survival and may serve as a diagnostic marker and therapeutic target in obese TNBC patients. |
| Description: |
Adipocyte-derived exosomal circCRIM1 is up-regulated in TNBC patients with high body fat percentage and is associated with poorer survival. It promotes TNBC proliferation, tumor growth, invasion and metastasis by sponging miR-503-5p, activating OGA, and suppressing FBP1 via reduced protein stability and increased ubiquitination. The study suggests exo-circCRIM1 as a potential diagnostic biomarker and therapeutic target for obese TNBC patients. |
| Confidence score: |
0.8319 |